{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:40:39Z","timestamp":1754484039176},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.medcli.2013.11.035","type":"journal-article","created":{"date-parts":[[2014,2,22]],"date-time":"2014-02-22T14:15:28Z","timestamp":1393078528000},"page":"389-396","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Coste por paciente con respuesta a romiplostim y rituximab en el tratamiento de la trombocitopenia inmune primaria en Espa\u00f1a"],"prefix":"10.1016","volume":"144","author":[{"given":"M. Fernanda","family":"L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Eva","family":"Mingot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Vicente Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignasi","family":"Campos Tapias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.11.035_bib0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.11.035_bib0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.2009.01247.x","article-title":"The incidence of idiopathic thrombocytopenic purpura among adults: A population-based study and literature review","volume":"83","author":"Abrahamson","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.medcli.2013.11.035_bib0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database","volume":"145","author":"Schoonen","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.11.035_bib0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2008.07464.x","article-title":"Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: Results from two randomized, placebo-controlled trials","volume":"144","author":"George","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.11.035_bib0025","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1185\/03007990802377461","article-title":"Health-related quality of life of immune thrombocytopenic purpura patients: Results from a web-based survey","volume":"24","author":"Snyder","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.medcli.2013.11.035_bib0030","unstructured":"Nplate\u00ae (romiplostim). Ficha t\u00e9cnica [consultado 2 Nov 2012]. Disponible en: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000942\/human_med_000938.jsp&mid=WC0b01ac058001d124"},{"key":"10.1016\/j.medcli.2013.11.035_bib0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.medcli.2011.11.011","article-title":"Diagn\u00f3stico, tratamiento y seguimiento de la trombocitopenia inmune primaria","volume":"138","author":"Sanz","year":"2012","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.11.035_bib0040","unstructured":"Mabthera\u00ae (rituximab). Ficha t\u00e9cnica [consultado 2 Nov 2012]. Disponible en: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000165\/human_med_000897.jsp&mid=WC0b01ac058001d124"},{"key":"10.1016\/j.medcli.2013.11.035_bib0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00277-010-1087-x","article-title":"Costs of managing severe immune thrombocytopenia in adults: A retrospective analysis","volume":"90","author":"Khellaf","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.medcli.2013.11.035_bib0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00019053-199813030-00002","article-title":"The role of cost-consequence analysis in healthcare decision-making","volume":"13","author":"Mauskopf","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.medcli.2013.11.035_bib0055","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1185\/03007995.2012.684046","article-title":"A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia","volume":"28","author":"Weitz","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.medcli.2013.11.035_bib0060","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1079\/PHN2002396","article-title":"Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"5","author":"Haftenberger","year":"2002","journal-title":"Public Health Nutr"},{"key":"10.1016\/j.medcli.2013.11.035_bib0065","unstructured":"Cornell University Medical Center Website. Formula of DuBois and DuBois [consultado 25 Ene 2011]. Disponible en: http:\/\/www-users.med.cornell.edu\/\u223cspon\/picu\/calc\/bsacalc.htm"},{"key":"10.1016\/j.medcli.2013.11.035_bib0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00277-011-1283-3","article-title":"Efficacy of rituximab in immune thrombocytopenic purpura: A retrospective survey","volume":"91","author":"Brah","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.medcli.2013.11.035_bib0075","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos [consultado 2 Nov 2011]. Disponible en: https:\/\/botplus.portalfarma.com"},{"key":"10.1016\/j.medcli.2013.11.035_bib0080","unstructured":"Decreto 160\/2010, do 23 de setembro, polo que se establecen as tarifas dos servizos sanitarios prestados nos centros dependentes do Servizo Galego de Sa\u00fade e nas fundaci\u00f3ns p\u00fablicas sanitarias [consultado 6 Nov 2011]. Disponible en: http:\/\/www.csi-f.es\/es\/node\/52533"},{"key":"10.1016\/j.medcli.2013.11.035_bib0085","unstructured":"Institut Catal\u00e0 de la Salut. Departament de Salut. Resoluci\u00f3n SLT\/383\/2009, de 21 de enero, sobre la revisi\u00f3n de precios p\u00fablicos correspondientes a los servicios sanitarios que presta el Instituto Catal\u00e1n de la Salud. Diari Oficial de la Generalitat de Catalunya; 2009. p. 14854 [consultado 6 Nov 2011]. Disponible en: https:\/\/www.gencat.cat\/eadop\/imagenes\/5325\/09042029.pdf"},{"key":"10.1016\/j.medcli.2013.11.035_bib0090","unstructured":"Gobierno del Principado de Asturias. Decreto 87\/2009, de 29 de julio, por el que se establecen los precios p\u00fablicos a aplicar por el Servicio de Salud del Principado de Asturias por la prestaci\u00f3n de servicios sanitarios. Bolet\u00edn Oficial del Principado de Asturias [consultado 6 Nov 2011]. Disponible en: https:\/\/sede.asturias.es\/bopa\/2009\/08\/11\/2009-19195.pdf"},{"key":"10.1016\/j.medcli.2013.11.035_bib0095","unstructured":"Servicio Navarro de Salud-Osasunbidea. Resoluci\u00f3n 882\/2010, de 3 de mayo, del Director Gerente del Servicio Navarro de Salud-Osasunbidea, por la que se actualizan las tarifas por prestaci\u00f3n de servicios en los centros y establecimientos asistenciales del Servicio Navarro de Salud-Osasunbidea, 2010 [consultado 6 Nov 2011]. Disponible en: http:\/\/legislacion.derecho.com\/resolucion-882-2010-03-mayo-2010-1-7-otros-2741628"},{"key":"10.1016\/j.medcli.2013.11.035_bib0100","unstructured":"Servicio C\u00e1ntabro de Salud. Orden SAN\/8\/2007, de 4 de abril, por la que se fijan las cuant\u00edas de los precios p\u00fablicos de los servicios sanitarios prestados por el Servicio C\u00e1ntabro de Salud, 2007 [consultado 6 Nov 2011]. Disponible en: http:\/\/legislacion.derecho.com\/orden-san-8-2007-16-abril-2008-consejeria-de-sanidad-951840"},{"key":"10.1016\/j.medcli.2013.11.035_bib0105","unstructured":"Decreto Legislativo 1\/2005, de 25 de febrero, del Consell de la Generalitat, por el que se aprueba el Texto Refundido de la Ley de Tasas de la Generalitat, 2005 [consultado 6 Nov 2011]. Disponible en: http:\/\/www.docv.gva.es\/portal\/ficha_disposicion_pc.jsp?sig=1539\/2005&L=1"},{"key":"10.1016\/j.medcli.2013.11.035_bib0110","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.21512","article-title":"Repeated courses of rituximab in chronic ITP: Three different regimens","volume":"84","author":"Hasan","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2013.11.035_bib0115","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.11.035_bib0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2013.11.035_bib0125","doi-asserted-by":"crossref","first-page":"A464","DOI":"10.1016\/S1098-3015(11)72974-6","article-title":"A pharmacoeconomic evaluation of romiplostim (Nplate) for the treatment of chronic immune thrombocytopenia (ITP)","volume":"13","author":"Brosa","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.medcli.2013.11.035_bib0130","doi-asserted-by":"crossref","first-page":"A415","DOI":"10.1016\/j.jval.2011.08.999","article-title":"Cost-consequence analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia (ITP) in France","volume":"14","author":"Chiche","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.medcli.2013.11.035_bib0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40258-013-0044-y","article-title":"Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland","volume":"11","author":"Lee","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.medcli.2013.11.035_bib0140","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2008-01-131029","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study","volume":"112","author":"Godeau","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.11.035_bib0145","unstructured":"L\u00f3pez M, Mingot M, Valc\u00e1rcel D, Vicente V. Treatment economic analysis: Clinical validation. Acta del cuestionario 28\/09\/11. Datos de archivo."},{"key":"10.1016\/j.medcli.2013.11.035_bib0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2007.06.007","article-title":"Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura","volume":"65","author":"Zhou","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.medcli.2013.11.035_bib0155","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2141.2012.09169.x","article-title":"Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: A meta-analysis","volume":"158","author":"Auger","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.11.035_bib0160","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.11.035_bib0165","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2011-12-309153","article-title":"How I treat immune thrombocytopenia: The choice between splenectomy or a medical therapy as a second-line treatment","volume":"120","author":"Ghanima","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.11.035_bib0170","unstructured":"Kuter DJ, Bussel JB, Newland A, Wasser JS, Lyons RM, George JN, et al. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): Final report from an open-label extension study. Paper presented at: 52nd ASH Annual Meeting and Exposition. Orlando, FL, December 4-7, 2010."},{"key":"10.1016\/j.medcli.2013.11.035_bib0175","unstructured":"Gisbert R, Brosa M. eSalud, base de datos de costes sanitarios en Espa\u00f1a. Oblikue Consulting, S. L. [consultado 6 Nov 2011]. Disponible en: http:\/\/www.oblikue.com\/bddcostes\/"},{"key":"10.1016\/j.medcli.2013.11.035_bib0180","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ajh.21463","article-title":"Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531)","volume":"84","author":"Pullarkat","year":"2009","journal-title":"Am J Hematol"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775314000128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775314000128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T07:58:40Z","timestamp":1538812720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775314000128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0025775314000128"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.11.035","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coste por paciente con respuesta a romiplostim y rituximab en el tratamiento de la trombocitopenia inmune primaria en Espa\u00f1a","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2013.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}